ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Mapping the global landscape of molecular glues in drug discovery: a bibliometric analysis from 2010 to 2024.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research Trends and Emerging Frontiers in Proteolysis Targeting Chimeras (PROTACs): A Bibliometric Analysis of 2630 Publications (2001-2025).Pharmaceuticals (Basel, Switzerland) · 2026Article
- A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular glues are an emerging class of small molecules that reprogram protein-protein interactions (PPIs), often by recruiting E3 ubiquitin ligases to neosubstrates, leading to targeted protein degradation. This bibliometric analysis systematically maps the molecular glue research landscape between 2010 and 2024, using the Dimensions database and visualization tools (VOSviewer and Bibliometrix). After screening, a curated set of 2491 publications was analyzed to assess trends in annual growth, geographic distribution, institutional output, author networks, and thematic hotspots. Results show rapid post-2020 expansion, driven by advances in structural biology, chemoproteomics, and computational design. The USA and China dominate in both productivity and collaboration networks, with European nations acting as strategic bridges and emerging contributors such as India, Japan, and South Korea showing thematic specialization. Beyond oncology-the dominant field-applications are expanding into neurodegenerative, inflammatory, and infectious diseases. Distinctive features of this study include pharmacology-focused tagging of E3 ligases (e.g., CRBN, DCAF15, RNF114), neosubstrates (IKZF1/3, RBM39, BRD4), and translational signals (clinical-phase and patient-linked studies). By capturing 2024 publications and providing therapeutic and mechanistic stratifications, this analysis complements earlier bibliometric studies and highlights opportunities for global collaboration, disease diversification, and translational development of molecular glues.
Indexed as
Identifiers
41108358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.